Glycan-binding polypeptides for use in treating and/or preventing helminthic infections, wherein the glycan-binding polypeptides bind N-glycans, O-glycans or lipoglycans, wherein the I. N-glycans are fucoside-containing oligo/polysaccharides and/or glycoconjugates, preferably (i) D-galacto-pyranosyl-β-1,4-L-fucopyranosyl-containing oligo/polysaccharides and/or glycoconjugates, more preferably D-galacto-pyranosyl-β-1,4-L-fucopyranosyl-α-1,6-GlcNAc-containing oligo/polysaccharides and/or glycoconjugates, more preferably GnGnF 6 Gal- and/or MMF 6 Gal-containing oligosaccharides and glycoconjugates, or (ii) L-fucopyranosyl-α-1,3- containing oligo/polysaccharides and/or glycoconjugates, more preferably L-fucopyranosyl-α-1,3-GlcNAc-containing oligo/polysaccharides and/or glycoconjugates, more preferably GnGnF 3 - and/or MMF 3 -containing oligosaccharides and glycoconjugates; II. O-glycans are galactoside-containing oligo/polysaccharides and/or glycoconjugates, preferably D-galacto-pyraraosyl-β-1,3-containing oligo/polysaccharides and/or glycoconjugates, more preferably D-galactopyranosyl-β-1,3-N-acetyl-D-gaiactasamino-pyranosyl-containing oligo/polysaccharides and/or glycoconjugates, most preferably D-galactopyranosyl-β-1,3-N-acetyl-D-galactosamino-pyranosyl-O-Ser/Thr containing oligo/polysaccharides and/or glycoconjugates; III. lipoglycans are galactoside-containing oligo/polysaccharides and/or glycoconjugates, preferably D-galacto-pyranosyl-α-1,3-containing oligo/polysaccharides and/or glycoconjugates, more preferably D-galactopyranosyl-α-1,3-N-acetyl-D-galactosamino-pyranosyl-containing oligo/polysaccharides and/or glycoconjugates, most preferably D-galactopyranosyl-α-1,3-N-acetyl-D-galactosamino-pyranosyl-β-1,4-N-acetyl-D-glucosamino-pyranosyl-containing oligo/polysaccharides and/or glycoconjugates. I. N-glycans are fucoside-containing oligo/polysaccharides and/or glycoconjugates, preferably (i) D-galacto-pyranosyl-β-1,4-L-fucopyranosyl-containing oligo/polysaccharides and/or glycoconjugates, more preferably D-galacto-pyranosyl-β-1,4-L-fucopyranosyl-α-1,6-GlcNAc-containing oligo/polysaccharides and/or glycoconjugates, more preferably GnGnF 6 Gal- and/or MMF 6 Gal-containing oligosaccharides and glycoconjugates, or (ii) L-fucopyranosyl-α-1,3- containing oligo/polysaccharides and/or glycoconjugates, more preferably L-fucopyranosyl-α-1,3-GlcNAc-containing oligo/polysaccharides and/or glycoconjugates, more preferably GnGnF 3 - and/or MMF 3 -containing oligosaccharides and glycoconjugates; (i) D-galacto-pyranosyl-β-1,4-L-fucopyranosyl-containing oligo/polysaccharides and/or glycoconjugates, more preferably D-galacto-pyranosyl-β-1,4-L-fucopyranosyl-α-1,6-GlcNAc-containing oligo/polysaccharides and/or glycoconjugates, more preferably GnGnF 6 Gal- and/or MMF 6 Gal-containing oligosaccharides and glycoconjugates, or (ii) L-fucopyranosyl-α-1,3- containing oligo/polysaccharides and/or glycoconjugates, more preferably L-fucopyranosyl-α-1,3-GlcNAc-containing oligo/polysaccharides and/or glycoconjugates, more preferably GnGnF 3 - and/or MMF 3 -containing oligosaccharides and glycoconjugates; II. O-glycans are galactoside-containing oligo/polysaccharides and/or glycoconjugates, preferably D-galacto-pyraraosyl-β-1,3-containing oligo/polysaccharides and/or glycoconjugates, more preferably D-galactopyranosyl-β-1,3-N-acetyl-D-gaiactasamino-pyranosyl-containing oligo/polysaccharides and/or glycoconjugates, most preferably D-galactopyranosyl-β-1,3-N-acetyl-D-galactosamino-pyranosyl-O-Ser/Thr containing oligo/polysaccharides and/or glycoconjugates; III. lipoglycans are galactoside-containing oligo/polysaccharides and/or glycoconjugates, preferably D-galacto-pyranosyl-α-1,3-containing oligo/polysaccharides and/or glycoconjugates, more preferably D-galactopyranosyl-α-1,3-N-acetyl-D-galactosamino-pyranosyl-containing oligo/polysaccharides and/or glycoconjugates, most preferably D-galactopyranosyl-α-1,3-N-acetyl-D-galactosamino-pyranosyl-β-1,4-N-acetyl-D-glucosamino-pyranosyl-containing oligo/polysaccharides and/or glycoconjugates.